ArticleApoptosis : an international journal on programmed cell death2026
Berberine inhibits ISG15 and pyroptosis to attenuate diabetic kidney disease inflammation and fibrosis.
Article in Apoptosis : an international journal on programmed cell death, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Regulated cell death: a multidimensional regulatory network in the pathogenesis of renal fibrosis.Apoptosis : an international journal on programmed cell death · 2026Review
- Tubular injury in diabetic kidney disease: a focus on regulated cell death.Frontiers in endocrinology · 2026Review
- Multi-omics and machine learning reveal LYZ and ISG15 as diagnostic and therapeutic targets in autoimmune-mediated chronic kidney disease.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Diabetic kidney disease (DKD) is a microvascular complication of diabetes accompanied by inflammation and tubular fibrosis. Berberine (BBR), a plant alkaloid and traditional Chinese medicine, has been shown to have beneficial effects on DKD. However, its mechanism underlying its therapeutic effects in DKD remain to be fully elucidated. Herein, we investigated the protective effects of BBR on STZ/HFD-induced DKD mice and high glucose (HG)-treated renal tubular epithelial cells (TECs). Results showed that BBR reduced inflammation and tubular fibrosis in DKD mice. Meanwhile, BBR also reversed HG-induced inflammation and fibrosis in TECs. Mechanistically, qPCR and western blotting assays revealed that BBR abolished the HG-induced upregulation of ISG15 and the changes in the expression of pyroptosis-related proteins. Furthermore, overexpression of ISG15 in kidney and TECs significantly exacerbated renal tubular cell injury and abolished the protective effect of BBR against DKD. In conclusion, these results demonstrated that BBR can attenuate inflammation and tubular fibrosis in DKD by inhibiting ISG15 and pyroptosis, providing a new potential strategy for the treatment of DKD and highlighting the therapeutic potential of BBR in mitigating renal injury and fibrosis.
Indexed as
Identifiers
41663781What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.